You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HER2-neg

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Carcinoma Trial in Houston (biological, drug, other)

Not yet recruiting
  • Breast Carcinoma
  • eftilagimod alpha
  • +2 more
  • Houston, Texas
    Oncology Consultants
Feb 17, 2023

Breast Cancer Trial in New Haven (Everolimus)

Terminated
Has Results
  • Breast Cancer
  • New Haven, Connecticut
    Yale University
Jan 12, 2022

HER2-positive Breast Cancer Trial in France (2 FES-PET Imaging will be performed:)

Terminated
  • HER2-positive Breast Cancer
  • 2 FES-PET Imaging will be performed:
  • Albi, France
  • +5 more
Jan 27, 2022

Metastatic Breast Adenocarcinoma, Breast Cancer Trial in Switzerland (CR1447)

Active, not recruiting
  • Metastatic Breast Adenocarcinoma
  • Breast Cancer
  • Aarau, Switzerland
  • +12 more
Feb 3, 2022

HER2-positive Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer Trial in Belgium, France (Pertuzumab and

Recruiting
  • HER2-positive Breast Cancer
  • +3 more
  • Pertuzumab and tratuzumab fixed dose combination
  • Trastuzumab emtansine
  • Auchenflower, Australia
  • +84 more
Jan 16, 2023

HER2 Low and Describe SoC, Treatment Patterns, and Outcome in

Completed
  • Breast Cancer
  • None (Observational study)
  • Pittsburgh, Pennsylvania
  • +12 more
May 25, 2022

Breast Cancer, HER2-positive Breast Cancer Trial in São Paulo (PHESGO)

Not yet recruiting
  • Breast Cancer
  • HER2-positive Breast Cancer
  • São Paulo, Brazil
    Centro Paulista de Oncologia (Oncoclínicas)
Oct 3, 2023

HER2-low in Unresectable and/or Metastatic Breast Cancer

Not yet recruiting
  • Breast Neoplasms, Breast Cancer, Breast Carcinoma, Genes, HER-2, Genes, HER2
    • (no location specified)
    Nov 6, 2023

    18F-HER2 PET Trial in Hangzhou (18F-HER2 PET)

    Not yet recruiting
    • 18F-HER2 PET
    • 18F-HER2 PET
    • Hangzhou, Zhejiang, China
      The First Affiliated Hospital, Zhejiang University School of med
    Aug 2, 2023

    HER2 Expression and Clinical Pathological Characteristics in

    Recruiting
    • HER2 Expression and Clinical Pathological Characteristics in Prostate Cancer
    • Collect HER2 expression in prostate cancer patients
    • Jinan, Shandong, China
      Qilu hospital
    Nov 17, 2023

    HER2-low in Metastatic Breast Cancer Patients

    Not yet recruiting
    • HER2-negative
      • (no location specified)
      Nov 9, 2023

      HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Trial (SHR-A1811, Ramucirumab / Paclitaxel/

      Not yet recruiting
      • HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
      • SHR-A1811
      • Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan
      • (no location specified)
      Nov 6, 2023

      HER2-positive Advanced Breast Cancer Patients Treated With ADC

      Recruiting
      • Breast Cancer
      • HER2 expression of circulating tumor cells
      • Beijing, Beijing, China
        The Fifth Medical Center of PLA General Hospital
      Apr 18, 2023

      HER2-low Advanced Breast Cancer Patients Treated With ADC

      Recruiting
      • Breast Cancer
      • HER2 expression of circulating tumor cells
      • Beijing, Beijing, China
        The Fifth Medical Center of PLA General Hospital
      Apr 18, 2023

      Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8

      Active, not recruiting
      Has Results
      • Anatomic Stage II Breast Cancer AJCC v8
      • +16 more
      • Durvalumab
      • Tremelimumab
      • Houston, Texas
        M D Anderson Cancer Center
      Aug 18, 2022

      Breast Cancer Trial (Trastuzumab Deruxtecan)

      Not yet recruiting
      • Breast Cancer
      • Trastuzumab Deruxtecan
      • (no location specified)
      Jul 10, 2023

      Solid Tumor Trial in Shenyang (Intravenous infusion anti-HER2-CAR-T cell)

      Not yet recruiting
      • Solid Tumor
      • Intravenous infusion anti-HER2-CAR-T cell
      • Shenyang, Liaoning, China
        Phase I Clinical Trials Center Of The First Hospital of China Me
      Oct 30, 2023

      Breast Cancer, Metastatic Breast Cancer, HER2-positive Breast Cancer Trial in Boston (Cessation of anti-HER2 treatment)

      Not yet recruiting
      • Breast Cancer
      • +2 more
      • Cessation of anti-HER2 treatment
      • Boston, Massachusetts
      • +1 more
      Feb 9, 2023

      HER2-positive Gastric Cancer, Immunotherapy Trial in Shanghai (Disitamab Vedotin combined with fruquintinib and Tislelizumab)

      Recruiting
      • HER2-positive Gastric Cancer
      • Immunotherapy
      • Disitamab Vedotin combined with fruquintinib and Tislelizumab
      • Shanghai, Shanghai, China
        Fudan University Shanghai Cancer Center
      Aug 8, 2023

      Survival Rate of HER2-Low Breast Cancer Patients

      Completed
      • HER2 Low Breast Carcinoma
      • immunohistochemistry (IHC) and in situ hybridization (ISH) Test
      • (no location specified)
      Mar 2, 2023

      HER2-positive Breast Cancer Trial (Standard of Care Adjuvant Breast Radiation, Standard of Care HER2-targeted Therapy Without

      Not yet recruiting
      • HER2-positive Breast Cancer
      • Standard of Care Adjuvant Breast Radiation
      • Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation
      • (no location specified)
      Jan 20, 2023

      HER2-positive Colorectal Cancer, HER2-positive Biliary Tract Cancer Trial in Beijing (KN026, KN046, XELOX)

      Not yet recruiting
      • HER2-positive Colorectal Cancer
      • HER2-positive Biliary Tract Cancer
      • Beijing, State*, China
        Peking University cancer hospital & institution
      Aug 2, 2023

      HER2 Low Breast Carcinoma Trial (SHR-A1811 for injection)

      Not yet recruiting
      • HER2 Low Breast Carcinoma
      • SHR-A1811 for injection
      • (no location specified)
      Jun 12, 2023

      Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2

      Recruiting
      • HER2-positive Breast Cancer
      • Early-stage Breast Cancer
      • pyrotinib combined with Capecitabine
      • treatment of physician's choice
      • Beijing, Beijing, China
        Peking Union Medical College Hospital
      Sep 6, 2023

      HER2 Positive Advanced Solid Tumors Trial (HypoSti.CAR-HER2 T cells, Albumin-bound paclitaxel, Cyclophosphamide)

      Not yet recruiting
      • HER2 Positive Advanced Solid Tumors
      • HypoSti.CAR-HER2 T cells
      • +2 more
      • (no location specified)
      Jan 12, 2023